Published in J Virol on April 01, 2004
Change in hepatitis B virus large surface antigen variant prevalence 13 years after implementation of a universal vaccination program in China. J Virol (2013) 1.31
Detecting hepatitis B surface antigen mutants. Emerg Infect Dis (2006) 1.16
Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol (2006) 1.10
Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol (2009) 1.08
Hepatitis B Virus e Antigen Variants. Int J Med Sci (2005) 1.04
Impairment of hepatitis B virus virion secretion by single-amino-acid substitutions in the small envelope protein and rescue by a novel glycosylation site. J Virol (2010) 1.02
Critical role of the 36-nucleotide insertion in hepatitis B virus genotype G in core protein expression, genome replication, and virion secretion. J Virol (2007) 0.98
Hepatitis B virus (HBV) surface antigen interacts with and promotes cyclophilin a secretion: possible link to pathogenesis of HBV infection. J Virol (2010) 0.94
Chimeric constructs between two hepatitis B virus genomes confirm transcriptional impact of core promoter mutations and reveal multiple effects of core gene mutations. Virology (2009) 0.93
Impaired virion secretion by hepatitis B virus immune escape mutants and its rescue by wild-type envelope proteins or a second-site mutation. J Virol (2012) 0.90
Spontaneous HBsAg loss in Korean patients: relevance of viral genotypes, S gene mutations, and covalently closed circular DNA copy numbers. Clin Mol Hepatol (2014) 0.89
Mutations associated with occult hepatitis B virus infection result in decreased surface antigen expression in vitro. J Viral Hepat (2012) 0.89
Improved method for rapid and efficient determination of genome replication and protein expression of clinical hepatitis B virus isolates. J Clin Microbiol (2011) 0.88
Identification of cellular membrane proteins interacting with hepatitis B surface antigen using yeast split-ubiquitin system. Int J Med Sci (2005) 0.80
Specific amino acid substitutions in the S protein prevent its excretion in vitro and may contribute to occult hepatitis B virus infection. J Virol (2013) 0.77
The infection efficiency and replication ability of circularized HBV DNA optimized the linear HBV DNA in vitro and in vivo. Int J Mol Sci (2015) 0.77
Investigation of a Novel Hepatitis B Virus Surface Antigen (HBsAg) Escape Mutant Affecting Immunogenicity. PLoS One (2017) 0.75
Replication of the genome of a hepatitis B--like virus by reverse transcription of an RNA intermediate. Cell (1982) 16.71
Vaccine-induced escape mutant of hepatitis B virus. Lancet (1990) 5.31
Inhibition of secretion of hepatitis B surface antigen by a related presurface polypeptide. Science (1986) 3.01
Expression of hepatitis B virus large envelope polypeptide inhibits hepatitis B surface antigen secretion in transgenic mice. J Virol (1986) 2.94
Genetic relatedness of hepatitis B viral strains of diverse geographical origin and natural variations in the primary structure of the surface antigen. J Gen Virol (1993) 2.50
Relationship between viral DNA synthesis and virion envelopment in hepatitis B viruses. J Virol (1996) 1.93
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
A dominant hepatitis B virus population defective in virus secretion because of several S-gene mutations from a patient with fulminant hepatitis. Hepatology (2001) 1.78
A short linear sequence in the pre-S domain of the large hepatitis B virus envelope protein required for virion formation. J Virol (1997) 1.78
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
Infectious hepatitis B virus variant defective in pre-S2 protein expression in a chronic carrier. Virology (1993) 1.75
Prevalence of naturally occurring surface gene variants of hepatitis B virus in nonimmunized surface antigen-negative Chinese carriers. Hepatology (2001) 1.61
Role of the pre-S2 domain of the large envelope protein in hepatitis B virus assembly and infectivity. J Virol (1998) 1.57
Replication capacities of natural and artificial precore stop codon mutants of hepatitis B virus: relevance of pregenome encapsidation signal. Virology (1992) 1.47
Mutational analysis of the cysteine residues in the hepatitis B virus small envelope protein. J Virol (1993) 1.45
Mapping of amino acid side chains on the surface of hepatitis B virus capsids required for envelopment and virion formation. J Virol (2003) 1.42
Low-level secretion of human hepatitis B virus virions caused by two independent, naturally occurring mutations (P5T and L60V) in the capsid protein. J Virol (2000) 1.41
A frequent, naturally occurring mutation (P130T) of human hepatitis B virus core antigen is compensatory for immature secretion phenotype of another frequent variant (I97L). J Virol (2000) 1.22
Intracellular hepadnavirus nucleocapsids are selected for secretion by envelope protein-independent membrane binding. J Virol (2000) 1.21
Duck hepatitis B virus virion secretion requires a double-stranded DNA genome. J Virol (2003) 1.19
Effect of mutations in the small envelope protein of hepatitis B virus on assembly and secretion of hepatitis delta virus. Virology (1998) 1.13
Altered antigenicity of 'a' determinant variants of hepatitis B virus. J Gen Virol (1997) 1.13
Hepatitis B virus assembly is sensitive to changes in the cytosolic S loop of the envelope proteins. Virology (2000) 1.12
Characterization of two hepatitis B virus populations isolated from a hepatitis B surface antigen-negative patient. Hepatology (2002) 1.10
Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology (2003) 1.08
Deficiency in virion secretion and decreased stability of the hepatitis B virus immune escape mutant G145R. Hepatology (2003) 1.02
Coexistence of two distinct secretion mutations (P5T and I97L) in hepatitis B virus core produces a wild-type pattern of secretion. J Virol (2003) 0.99
Evolution of hepatitis B virus sequence from a liver transplant recipient with rapid breakthrough despite hepatitis B immune globulin prophylaxis and lamivudine therapy. J Med Virol (2003) 0.98
Selection of a secretion-incompetent mutant in the serum of a patient with severe hepatitis B. Gastroenterology (2003) 0.86
Emergence of an S gene mutant during thymosin alpha1 therapy in a patient with chronic hepatitis B. J Infect Dis (1998) 0.79
Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease--is this type 3 diabetes? J Alzheimers Dis (2005) 3.78
Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology (2010) 3.55
Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: link to brain reductions in acetylcholine. J Alzheimers Dis (2005) 2.12
Review of insulin and insulin-like growth factor expression, signaling, and malfunction in the central nervous system: relevance to Alzheimer's disease. J Alzheimers Dis (2005) 2.11
Alzheimer's disease is type 3 diabetes-evidence reviewed. J Diabetes Sci Technol (2008) 1.97
Functional consequences of frizzled-7 receptor overexpression in human hepatocellular carcinoma. Gastroenterology (2004) 1.88
Risk assessment of hepatitis B virus-related hepatocellular carcinoma development using liver stiffness measurement (FibroScan). Hepatology (2011) 1.87
Intracerebral streptozotocin model of type 3 diabetes: relevance to sporadic Alzheimer's disease. J Alzheimers Dis (2006) 1.82
Persistent hepatitis B viral replication affects recurrence of hepatocellular carcinoma after curative resection. Liver Int (2007) 1.80
Antisense oligodeoxynucleotides directed against aspartyl (asparaginyl) beta-hydroxylase suppress migration of cholangiocarcinoma cells. J Hepatol (2003) 1.80
Genome replication, virion secretion, and e antigen expression of naturally occurring hepatitis B virus core promoter mutants. J Virol (2003) 1.79
Alcohol and hepatitis C virus--interactions in immune dysfunctions and liver damage. Alcohol Clin Exp Res (2010) 1.77
The mitochondrial uncoupling protein-2 promotes chemoresistance in cancer cells. Cancer Res (2008) 1.71
Number of target lesions for EASL and modified RECIST to predict survivals in hepatocellular carcinoma treated with chemoembolization. Clin Cancer Res (2012) 1.67
A role for natural regulatory T cells in the pathogenesis of experimental cerebral malaria. Am J Pathol (2007) 1.67
Therapeutic rescue of neurodegeneration in experimental type 3 diabetes: relevance to Alzheimer's disease. J Alzheimers Dis (2006) 1.65
Aspartyl-asparagyl beta hydroxylase over-expression in human hepatoma is linked to activation of insulin-like growth factor and notch signaling mechanisms. Hepatology (2006) 1.64
The accuracy of noninvasive methods in predicting the development of hepatocellular carcinoma and hepatic decompensation in patients with chronic hepatitis B. J Clin Gastroenterol (2012) 1.63
Clarification required for the definition of hepatitis B virus subgenotypes C1 and C2. Intervirology (2009) 1.60
Functional interaction between Wnt3 and Frizzled-7 leads to activation of the Wnt/beta-catenin signaling pathway in hepatocellular carcinoma cells. J Hepatol (2008) 1.56
Natural history of hepatitis B virus-related cirrhotic patients hospitalized to control ascites. J Gastroenterol Hepatol (2008) 1.55
Wnt/Frizzled signaling in hepatocellular carcinoma. Front Biosci (2006) 1.50
Loss of Raf kinase inhibitor protein promotes cell proliferation and migration of human hepatoma cells. Gastroenterology (2006) 1.49
Molecular indices of oxidative stress and mitochondrial dysfunction occur early and often progress with severity of Alzheimer's disease. J Alzheimers Dis (2006) 1.48
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B. Gut (2013) 1.46
Prospective validation of P2/MS noninvasive index using complete blood counts for detecting oesophageal varices in B-viral cirrhosis. Liver Int (2010) 1.46
Variability in liver stiffness values from different intercostal spaces. Liver Int (2009) 1.45
Signal transduction cascades and hepatitis B and C related hepatocellular carcinoma. Hepatology (2006) 1.44
Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLoS One (2012) 1.44
Performance of transient elastography for the staging of liver fibrosis in patients with chronic hepatitis B: a meta-analysis. PLoS One (2012) 1.43
Wnt signaling and hepatocarcinogenesis: molecular targets for the development of innovative anticancer drugs. J Hepatol (2013) 1.40
Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol (2004) 1.39
Expression of uncoupling protein-2 in human colon cancer. Clin Cancer Res (2004) 1.37
Pilot clinical trial of localized concurrent chemoradiation therapy for locally advanced hepatocellular carcinoma with portal vein thrombosis. Cancer (2008) 1.36
Usefulness of FibroScan for detection of early compensated liver cirrhosis in chronic hepatitis B. Dig Dis Sci (2008) 1.35
Hepatocellular carcinoma presenting with bone metastasis: clinical characteristics and prognostic factors. J Cancer Res Clin Oncol (2008) 1.34
Oncogenic role of the frizzled-7/beta-catenin pathway in hepatocellular carcinoma. J Hepatol (2005) 1.33
Involvement of the p38 mitogen-activated protein kinase cascade in hepatocellular carcinoma. Cancer (2003) 1.32
Acute ethanol exposure inhibits insulin signaling in the liver. Hepatology (2007) 1.31
The human cervical cancer oncogene protein is a biomarker for human hepatocellular carcinoma. Cancer Res (2004) 1.30
Hepatitis C virus core protein stimulates hepatocyte growth: correlation with upregulation of wnt-1 expression. Hepatology (2005) 1.30
Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology (2011) 1.29
Insulin resistance in experimental alcohol-induced liver disease. J Gastroenterol Hepatol (2008) 1.28
Controlled attenuation parameter (CAP) for detection of hepatic steatosis in patients with chronic liver diseases: a prospective study of a native Korean population. Liver Int (2013) 1.27
Prevention of hepatocellular carcinoma. N Engl J Med (2004) 1.27
Potential role of PTEN phosphatase in ethanol-impaired survival signaling in the liver. Hepatology (2003) 1.26
HBV genotypes: relevance to natural history, pathogenesis and treatment of chronic hepatitis B. Antivir Ther (2011) 1.26
Validation of FIB-4 and comparison with other simple noninvasive indices for predicting liver fibrosis and cirrhosis in hepatitis B virus-infected patients. Liver Int (2010) 1.25
MDM2 and p53 polymorphisms are associated with the development of hepatocellular carcinoma in patients with chronic hepatitis B virus infection. Carcinogenesis (2008) 1.25
Prediction of liver-related events using fibroscan in chronic hepatitis B patients showing advanced liver fibrosis. PLoS One (2012) 1.24
Uncoupling protein-2 deficiency promotes oxidant stress and delays liver regeneration in mice. Hepatology (2004) 1.24
MRP2 haplotypes confer differential susceptibility to toxic liver injury. Pharmacogenet Genomics (2007) 1.23
Insulin and insulin-like growth factor resistance with neurodegeneration in an adult chronic ethanol exposure model. Alcohol Clin Exp Res (2007) 1.23
Aspartyl-(asparaginyl)-beta-hydroxylase regulates hepatocellular carcinoma invasiveness. J Hepatol (2006) 1.22
Overexpression of endoplasmic reticulum molecular chaperone GRP94 and GRP78 in human lung cancer tissues and its significance. Cancer Detect Prev (2005) 1.22
Alcohol-induced disruption of endocrine signaling. Alcohol Clin Exp Res (2007) 1.21
Insulin resistance and neurodegeneration: roles of obesity, type 2 diabetes mellitus and non-alcoholic steatohepatitis. Curr Opin Investig Drugs (2009) 1.21
Noninvasive models to predict liver cirrhosis in patients with chronic hepatitis B. Liver Int (2007) 1.21
PPARdelta agonist attenuates alcohol-induced hepatic insulin resistance and improves liver injury and repair. J Hepatol (2009) 1.20
Acute and chronic alcohol abuse modulate immunity. Alcohol Clin Exp Res (2006) 1.18
Long-term adefovir dipivoxil monotherapy for up to 5 years in lamivudine-resistant chronic hepatitis B. Antivir Ther (2010) 1.18
Acetaldehyde adducts in alcoholic liver disease. Oxid Med Cell Longev (2010) 1.18
Efficacy of adefovir add-on lamivudine rescue therapy compared with switching to entecavir monotherapy in patients with lamivudine-resistant chronic hepatitis B. J Med Virol (2010) 1.18
Liver stiffness measurement in combination with noninvasive markers for the improved diagnosis of B-viral liver cirrhosis. J Clin Gastroenterol (2009) 1.17
Comparison of rifaximin and lactulose for the treatment of hepatic encephalopathy: a prospective randomized study. Yonsei Med J (2005) 1.17
Normal controlled attenuation parameter values: a prospective study of healthy subjects undergoing health checkups and liver donors in Korea. Dig Dis Sci (2014) 1.16
Inhibition of p53 attenuates steatosis and liver injury in a mouse model of non-alcoholic fatty liver disease. J Hepatol (2012) 1.16
A liver stiffness measurement-based, noninvasive prediction model for high-risk esophageal varices in B-viral liver cirrhosis. Am J Gastroenterol (2010) 1.15
Long-term outcome of chronic hepatitis B based on histological grade and stage. J Gastroenterol Hepatol (2007) 1.15
Early α-fetoprotein response as a predictor for clinical outcome after localized concurrent chemoradiotherapy for advanced hepatocellular carcinoma. Liver Int (2010) 1.15
Nitrosamine exposure causes insulin resistance diseases: relevance to type 2 diabetes mellitus, non-alcoholic steatohepatitis, and Alzheimer's disease. J Alzheimers Dis (2009) 1.15
Liver stiffness measurement using acoustic radiation force impulse (ARFI) elastography and effect of necroinflammation. Dig Dis Sci (2012) 1.14
Risk assessment of esophageal variceal bleeding in B-viral liver cirrhosis by a liver stiffness measurement-based model. Am J Gastroenterol (2011) 1.14
Role of the aspartyl-asparaginyl-beta-hydroxylase gene in neuroblastoma cell motility. Lab Invest (2002) 1.12
Prospective validation of FibroTest in comparison with liver stiffness for predicting liver fibrosis in Asian subjects with chronic hepatitis B. PLoS One (2012) 1.12
How can we enhance the performance of liver stiffness measurement using FibroScan in diagnosing liver cirrhosis in patients with chronic hepatitis B? J Clin Gastroenterol (2010) 1.12
Lamivudine maintenance beyond one year after HBeAg seroconversion is a major factor for sustained virologic response in HBeAg-positive chronic hepatitis B. Hepatology (2010) 1.11
Activation of invariant NKT cells exacerbates experimental visceral leishmaniasis. PLoS Pathog (2008) 1.11
Repetitive short-course hepatic arterial infusion chemotherapy with high-dose 5-fluorouracil and cisplatin in patients with advanced hepatocellular carcinoma. Cancer (2007) 1.11
Point mutations upstream of hepatitis B virus core gene affect DNA replication at the step of core protein expression. J Virol (2006) 1.10
Evaluation of methods for monitoring drug resistance in chronic hepatitis B patients during lamivudine therapy based on mass spectrometry and reverse hybridization. Antivir Ther (2005) 1.10
Drastic reduction in the production of subviral particles does not impair hepatitis B virus virion secretion. J Virol (2009) 1.08
Hepatitis C virus and alcohol. Semin Liver Dis (2009) 1.08
Sequence variation upstream of precore translation initiation codon reduces hepatitis B virus e antigen production. Gastroenterology (2003) 1.08
Identification and characterization of clevudine-resistant mutants of hepatitis B virus isolated from chronic hepatitis B patients. J Virol (2010) 1.07
Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B. Antivir Ther (2011) 1.07
Activation of p53 enhances apoptosis and insulin resistance in a rat model of alcoholic liver disease. J Hepatol (2010) 1.07
Lack of UCP2 reduces Fas-mediated liver injury in ob/ob mice and reveals importance of cell-specific UCP2 expression. Hepatology (2006) 1.07